Join
Live feed
·
PRReleasevia Quantisnow
Actinium Pharmaceuticals Inc. (Delaware) logo

Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium

ByQuantisnow·Wall Street's wire, on your screen.
ATNM· Actinium Pharmaceuticals Inc. (Delaware)
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ATNM (Actinium Pharmaceuticals Inc. (Delaware)) and more on Quantisnow.

Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium | Quantisnow